DRES-10. DRD5 IS A MODULATOR OF GLIOMA SUSCEPTIBILITY TO DRD2 ANTAGONISM BY ONC201

ONC201 is the first selective antagonist of dopamine receptor D2 (DRD2) and D3 (DRD3) for clinical oncology that has exhibited preliminary clinical activity in high grade gliomas. We investigated DRD2 dysregulation in glioma and its role in ONC201 efficacy. Investigating CRISPR screens across a spec...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Vijay Prabhu, Varun, Madhukar, Neel, Gilvary, Coryandar, Kline, C Leah B, Tarapore, Rohinton, El-Deiry, Wafik, Doherty, Faye, VanEngelenburg, Alexander, Durrant, Jessica, Benes, Cyril, Oster, Wolfgang, Elemento, Olivier, Allen, Joshua
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216484/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.317
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados